Two Children With a Rare Epilepsy Mutation Show Improvement After Personalized Genetic Treatment

discovermagazine - Learn how personalized genetic therapy helped researchers treat two children with a rare form of epilepsy, enabling one to walk independently for the first time.

AI Summary: Two children with a rare, treatment‑resistant epilepsy mutation showed marked clinical improvement after receiving individualized genetic therapies—one via an antisense oligonucleotide tailored to the mutation. The cases underscore the promise of bespoke molecular medicines for devastating pediatric neurological disorders and hint that precision medicine can be both life‑changing and, yes, kind of miraculous.

#healthcare #pharmaceuticals #biotech #drugdevelopment #clinicaltrials #genetherapy #genetics #neuroscience

2 days / medicalxpress


Back to Top / Wed, July 22, 2026, 6:22 pm / permalink 27508 / 4 stories in 27 hrs /




Related Stories


Single‑infusion gene editing dramatically lowers LDL cholesterol in early trial / 7 wks

Drug-induced hibernation shows promise to limit stroke brain injury / 4 wks

Stem cells show potent promise as a diabetes treatment / 2 months

Mid‑stage Parkinson trial failure halts drug development plans / 2 months

Gene therapy restores hearing in about 90% of trial participants / 3 months

First-in-human trial primes immune system to accept donor livers / 3 months

Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 3 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Rural Health, Healthcare, Research Funding, Corporate Takeover and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.